J Clin Oncol: The use of carptin-yew alcohol in patients with metastasis squamous non-small cell lung cancer combined with Peboli pearl monoantigen can improve the quality of life in patients.

In the Phase 3 KEYNOTE-407 study, the addition of Peboli pearl monoantigen on the basis of carbap-yew alcohol/nabo-yew alcohol significantly improved the total survival, progressive survival and objective response rates of patients with previously untreated metastasis squamous non-small cell lung cancer (NSCLC), but had little effect on severe toxicity.
this article, we present keyNOTE-407 Patient Reporting Results (PRO).
patients were randomly subjected to 4 cycles of Peeber pearl monoantigen resistance 200 mg or placebo, once every 3 weeks, plus carpentin plus yew alcohol or nab-yew alcohol, and then received Peboli pearl monoanti or placebo for a total of 31 cycles.
To assess health-related quality of life (HRQoL) using the European Cancer Research and Treatment Organization's Quality of Life Questionnaire - Core 30 (QLQ-C30) and Quality of Life Questionnaire - Lung Cancer Module 13 (QLQ-LC13).
Key PRO endpoints are changes in QLQ-C30 Global Health/Quality of Life (GHS/QoL) scores from baseline to weeks 9 and 18 (platinum treatment period and later), as well as a compound endpoint deterioration time for cough, chest pain, or breathing difficulties in QLQ-C30 and QLQ-LC13.
results, a total of 554 and 553 patients completed the QLQ-C30 or 1 QLQ-LC13 assessment, respectively.
GHS/QoL score improved in the Peebery-Pearl single-anti-joint group (minimum multiplication of the baseline (LS) mean of 95%CI) change: week 9, 1.8 (-0.9 to 4.4) and week 18, 4.3 1.7 to 6.9), the placebo group's GHS/QoL score deteriorated (week 9, -1.8 (-4.4 to 0.7) and week 18, -0.57 (-3.3 to 2.2).)
the differences between the groups in the Peebery-Pearl single-resistance joint group (LS average score difference: week 9, 3.6 (95% CI, 0.3 to 6.9), P s .037; week 18, 4.9 s 1.4 to 8.3, P s. 0060).
two groups did not reach the mid-level time for worsening cough, chest pain, or breathing difficulties (HR, 0.79; 95% CI, 0.58 to 1.06) ;P .125).
, the results showed that adding Peebery-Pearl monoantigen to chemotherapy maintained or improved HRQoL measurements relative to the baseline, and improved the comparison of HRQoL with chemotherapy alone in weeks 9 and 18.
these results support the use of Peeberid monoantigen anti-plus chemotherapy as a first-line treatment for metastasis squamous NSCLC.
.